Developing a new treatment to prevent cancer recurrence
Targeting Aldehyde Dehydrogenase for Cancer Prevention
This study is looking at a new treatment that could help stop cancer from coming back and make current immunotherapy options work better by targeting a specific enzyme, and it's designed for people who are dealing with cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pennsylvania State Univ Hershey Med Ctr NIH-funded |
| Lab location | 1 site (Hershey, United States) |
| Project ID | NIH-10805445 on NIH RePORTER |
What this research studies
This research focuses on targeting the enzyme aldehyde dehydrogenase (ALDH) to prevent cancer recurrence and improve immunotherapy effectiveness. Researchers are developing a non-toxic broad-spectrum ALDH inhibitor that aims to eliminate cancer stem cells, which are responsible for recurrent resistant disease. The study involves testing this new inhibitor's efficacy in preclinical models, particularly in enhancing the effects of existing immunotherapies like anti-PD1. By addressing the immune suppression caused by ALDH+ cells, the research seeks to improve patient outcomes in cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that exhibit high levels of ALDH activity and are at risk for recurrence.
Not a fit: Patients with cancers that do not involve ALDH+ cancer stem cells may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that significantly reduces the chances of cancer recurrence and enhances the effectiveness of immunotherapy.
How similar studies have performed: While targeting ALDH in cancer treatment is a relatively novel approach, preliminary data suggest promising results in enhancing immunotherapy efficacy.
Where this research is happening
Hershey, United States
- Pennsylvania State Univ Hershey Med Ctr — Hershey, United States (Active)
Researchers
- Principal investigator: Robertson, Gavin P. — Pennsylvania State Univ Hershey Med Ctr
- Study coordinator: Robertson, Gavin P.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.